Teva Pharmaceutical Industries Ltd. ("Teva" or the Company) is an Israeli multinational pharmaceutical company that specializes primarily in generic drugs.

According to the Complaint, it is alleged that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business and operations. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that there was significant internal discord between the Board and Teva' s senior management during the Class Period (and in particular, significant differences between the Chairman of the Board and the CEO) concerning execution of the Company's strategies, including implementation of the critical Cost Cutting Program. As a result of the foregoing, the Company's stock traded at artificially inflated prices during the Class Period.

On July 8, 2014, an amended Complaint was filed.

On July 16, 2014, the Court issued an Order appointing lead Plaintiff and approving lead Counsel.

This case was voluntarily dismissed on March 4, 2015.